Lasa Supergenerics is locked at upper circuit limit of Rs. 47.50, up by 2.25 points or 4.97% from its previous closing of Rs. 45.25 on the BSE.
The scrip opened at Rs. 47.20 and has touched a high and low of Rs. 47.50 and Rs. 46.60 respectively. So far 12741 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 47.50 on 27-Feb-2020 and a 52 week low of Rs. 9.48 on 06-Aug-2019.
Last one week high and low of the scrip stood at Rs. 47.50 and Rs. 39.10 respectively. The current market cap of the company is Rs. 184.04 crore.
The promoters holding in the company stood at 36.80%, while Institutions and Non-Institutions held 0.03% and 63.17% respectively.
Lasa Supergenerics has acquired Harishree Aromatics And Chemicals which is in the manufacturing of Veterinary API & Other Pharmaceuticals Intermediates. This acquisition has been a strategic decision to restructure company’s current potential and a forward integrate.
In addition to the takeover of the manufacturing unit along with all other assets and liabilities whereas transferor is a debt free company, the amalgamation and consolidation will result in an increase in market share, product and services diversification, combined pool of reserves, investments and other assets giving it a competitive edge over its listed and unlisted peers.
Lasa Supergenerics, pioneer and amongst the leading players in the manufacturing of APIs in India through its catalyst chemistry expertise and fully backward integrated unit.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: